SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
DURECT Corporation Announces King Pharmaceuticals®, Inc.'s ELADUR(R) (TRANSDUR(R)-Bupivacaine) Phase II Study Results in Chronic Low Back Pain